By Paul Ziobro
Trevi Therapeutics said a study regarding the human-abuse potential of an oral drug to treat chronic cough in certain patients yielded positive results.
The company on Tuesday said that a study of oral nalbuphine showed clinical doses of the drug demonstrated a statistically significant lower "drug liking" compared with intravenous butorphanol. Meanwhile, a supratherpeutic dose was numerically lower than the intravenous butorphanol, but the results were not statistically significant.
James Cassella, Trevi's chief development officer, said the company was pleased with the results.
Trevi is developing the Haduvio, an oral naluphine extended release drug that treats chronic cough in patients with idiopathic pulmonary fibrosis and refractory chronic cough. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist, which are opioid receptors that play a key role in controlling cough.
Nalbuphine is currently unscheduled in the U.S. and has been for several decades, according to Jack Henningfield, vice president of research, health policy and abuse liability at Pinney Associates. Part of the study is to demonstrate that the drug doesn't pose the same safety risks as do other opioids that are often prescribed for chronic cough.
Write to Paul Ziobro at paul.ziobro@wsj.com
(END) Dow Jones Newswires
December 03, 2024 17:30 ET (22:30 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。